Relative Impact of Genotype and Enzyme Induction on the Metabolic Capacity of CYP2C9 in Healthy Volunteers
- 15 April 2009
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 86 (1) , 54-61
- https://doi.org/10.1038/clpt.2009.40
Abstract
Pharmacokinetics in individual subjects is determined by genes and environment. The relative contributions of enzyme induction and inherited genomic variation to cytochrome P450 enzyme 2C9 (CYP2C9) activity are unknown. In 130 volunteers, CYP2C9 activity was measured in vivo using tolbutamide as a probe drug. Tolbutamide was administered orally, and the pharmacokinetics of the drug was analyzed twice--before and after four doses of 450 mg rifampin. Mean total apparent clearances (Cl/F) in the genotype groups CYP2C9*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 before rifampin were 0.78, 0.74, 0.52, 0.40, and 0.13 l/h, respectively. After rifampin administration, these clearances increased in all genotype groups by a median factor of 1.9 (range 1.1-4.8). The combined effects of genes and environment could be predicted by a simple additive model. Thus, enzyme induction resulted in an approximately twofold difference in CYP2C9 activity, irrespective of the CYP2C9 genotypes. But the difference in activity levels between the CYP2C9*1/*1 and *3/*3 genotypes before the administration of rifampin was sixfold.Keywords
This publication has 42 references indexed in Scilit:
- Genetic variation at the CYP2C locus and its association with torsemide biotransformationThe Pharmacogenomics Journal, 2006
- Clinical consequences of cytochrome P450 2C9 polymorphismsClinical Pharmacology & Therapeutics, 2005
- The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendationsPersonalized Medicine, 2004
- Induction of Human CYP2C9 by Rifampicin, Hyperforin, and Phenobarbital Is Mediated by the Pregnane X ReceptorThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: In vitro and in vivo studiesClinical Pharmacology & Therapeutics, 2001
- Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepirideBritish Journal of Clinical Pharmacology, 2000
- Quantitative Analysis of Constitutive and Inducible CYPs mRNA Expression in the HepG2 Cell Line Using Reverse Transcription-Competitive PCRBiochemical and Biophysical Research Communications, 2000
- Cytochrome P4502C9: an enzyme of major importance in human drug metabolismBritish Journal of Clinical Pharmacology, 1998
- Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizersClinical Pharmacology & Therapeutics, 1990
- The mechanism of the warfarin-rifampin drug interaction in humansClinical Pharmacology & Therapeutics, 1987